Share

May 26, 2020; 94 (21) Special Editorial

COVID-19 is catalyzing the adoption of teleneurology

Brad C. Klein, Neil A. Busis
First published April 1, 2020, DOI: https://doi.org/10.1212/WNL.0000000000009494
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3566

Share

Article Information

vol. 94 no. 21 903-904
DOI: 
https://doi.org/10.1212/WNL.0000000000009494
PubMed: 
32238505
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 1, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Brad C. Klein, MD, MBA and
    2. Neil A. Busis, MD
  1. Brad C. Klein, MD, MBA and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Allergan, (2) Amgen, (3) Biohaven, (4) Eagalet, (5) Eli Lilly, (6) Lundbeck, (7) Promius, (8) Teva, (9) US WorldMeds.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Abington Neurological Associates, Ltd., Chief Operating Officer, 12 years

    Consultancies:

    1. (1) Allergan, (2) Amgen, (3) Biohaven, and (4) Promius

    Speakers' Bureaus:

    1. (1) Allergan, (2) Amgen, (3) Biohaven, (4) Eagalet, (5) Eli Lilly, (6) Lundbeck, (7) Promius, (8) Teva, (9) US WorldMeds.

    Other activities:

    1. Equity interest in AppsByDocs, LLC, makers of p-cog.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Alder, (2) Allergan, and (3) Eli Lilly

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Neil A. Busis, MD
    3. Scientific Advisory Boards:

    1. Alternate CPT Advisor for American Academy of Neurology on the CPT Advisory Committee. CPT is operated by the American Medical Association

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker at courses sponsored by the American Academy of Neurology

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Former Member of the American Academy of Neurology Board of Directors. Only travel expenses until April, 2017 were reimbursed.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Abington Hospital (B.C.K.), Department of Neurology, Thomas Jefferson University, Philadelphia, PA; and Department of Neurology (N.A.B.), NYU Langone Health, New York.
  1. Correspondence
    Dr. Klein bradcklein{at}gmail.com

Article usage

Article usage: April 2020 to October 2023

AbstractFullPdfSource
Apr 2020336901259Highwire
May 2020788600527Highwire
Jun 2020217327257Highwire
Jul 2020147241152Highwire
Aug 20207115681Highwire
Sep 2020110187128Highwire
Oct 202012221090Highwire
Nov 20206018093Highwire
Dec 2020198642Highwire
Jan 20212722755Highwire
Feb 20212722445Highwire
Mar 20211524345Highwire
Apr 20211923375Highwire
May 20212125539Highwire
Jun 20212423039Highwire
Jul 20211119336Highwire
Aug 20212231533Highwire
Sep 20211127241Highwire
Oct 20211726238Highwire
Nov 20211527342Highwire
Dec 2021819926Highwire
Jan 2022916424Highwire
Feb 2022928825Highwire
Mar 20221728827Highwire
Apr 20222025425Highwire
May 2022930623Highwire
Jun 2022823718Highwire
Jul 2022814218Highwire
Aug 2022713818Highwire
Sep 2022712115Highwire
Oct 2022712124Highwire
Nov 20221310313Highwire
Dec 20221010614Highwire
Jan 20231210020Highwire
Feb 2023169510Highwire
Mar 202366413Highwire
Apr 202354426Highwire
May 202347314Highwire
Jun 202374412Highwire
Jul 202366520Highwire
Aug 202369127Highwire
Sep 20237689Highwire
Oct 2023310928Highwire

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me

Recommended articles